DEVELOPING A NOVEL THERAPEUTIC FOR DIABETIC RETINOPATHY BY TARGETING THE HEPARIN-BINDING DOMAIN OF VEGF: ANTI-INFLAMMATION AND PROTECTIONOF THE DIABE

Schepens Eye Research Institute, Inc., The

Investigators